February 24, 2018

Atrial Fibrillation and Heart Health Event: Take Charge of Your Heart Health

The Preventive Cardiovascular Nurses Association (PCNA), in partnership with WomenHeart, Mended Hearts and The Society for Cardiac Angiography and Interventions, will host free heart health events. These 2-hour Saturday afternoon sessions were developed for you to learn more about atrial fibrillation, as well as taking care of your heart health, monitoring blood pressure, stents and cardiac rehab. Free heart healthy snacks will be provided and you’ll leave with free copies of new informational booklets on atrial fibrillation and blood pressure.

Locations and dates include:

Akron, OH — October 29
Asheville, NC — October 29
Jacksonville, FL — October 29
Charlottesville, VA — November 5

Register for a program near you


  1. mitralvalve2 says:

    This is certainly a marvelous article. Thank you for taking a few minutes to summarize this all out for us. It is a great guide!

  2. I appreciate your post and will subscribe to your rss feed so I can read anytime. Wonderful information



    I keep reading that most (or all) test comparisons of all meds other than Coumadin, are supposedly only tested on patients with nonvalvular AF, and since I DO HAVE a heart valve problem, along with AF, …..Then where do I come in relative to all these “new” meds to combat AF? I would really like to have an answer…..thank you very much, and I’ll be checking tomorrow…..10/28 on this site…….See you there, Lloyd

    • Lloyd,

      I’m sorry, I’ve been on the road for most of the past month (actually most of the past 3 months) so I am not replying as promptly as I’d like.

      I wish I had an answer for you about valvular afib and the new medications, but most are only approved by the FDA for nonvalvular afib. Valvular afib is less common than nonvalvular, so part of the issue is the difficulty of recruiting enough patients (and funding) a study on these drugs in valvular afib patients. In addition, those with certain types of replacement valves are on Coumadin already because of their valves, so that would significantly complicate the variables and endpoints in a clinical trial.

      I wish I had better information for you. Perhaps your doctors can address this concern.